Updated results from the phase 3 CASPIAN study further established first-line durvalumab with platinum-etoposide as a standard of care for ES-SCLC.
Sucharita Mistry, PhD
Sucharita Mistry is an Oncology Writer for the Haymarket oncology brands. She is a prolific medical writer with a vast background in hematology and medical oncology research. She had previously served as a faculty at the Icahn School of Medicine at Mount Sinai, where her research was focused on developing novel therapeutic strategies for prostate and breast cancer. In a subsequent role, she was a Biomedical Science Writer in the Division of Hematology-Medical Oncology at Weill Cornell Medicine. Sucharita holds a Master’s degree in Molecular Biology from Fairleigh Dickinson University and a Ph.D. in Cancer Biology from the State University of New York, Health Science Center at Brooklyn.
